Home » News » AIM News » Oncimmune Holdings plc makes key appointments to further strengthen management teams
Oncimmune Holdings Plc

Oncimmune Holdings plc makes key appointments to further strengthen management teams

Oncimmune Holdings plc (LON: ONC), a leading global immunodiagnostics group, has today announced the appointment of Professor Tariq Sethi as Chief Scientific Officer, Matthew Luttrell as Chief Commercial Officer and Cléa Rosenfeld as Head of Investor Relations.

Professor Tariq Sethi is a researcher, clinician and entrepreneur with over 35 years of combined academic and industry experience in the field of immunology, inflammation and Lung Cancer. Prior to joining Oncimmune, Tariq was Chief Physician Scientist, Vice President in the Clinical Discovery Unit AstraZeneca and Emeritus Professor of Respiratory Medicine King’s College London, having previously been Vice President in AstraZeneca’s Respiratory Immunology Autoimmunity Translational Medicine Unit and formally Professor of Respiratory Medicine and Lung Cancer at Edinburgh University. He is also founder of Galecto Biotech. His research interests focus on chronic inflammatory diseases and fibrosis and the interaction between inflammation and lung cancer. Given his skillset and experience Tariq is very well placed to direct and lead Oncimmune’s discovery research, translational and clinical programmes effectively. Tariq joins Oncimmune as from 1 October 2019 as its Chief Scientific Officer, and will also become part of the Senior Leadership Team.

Matthew Luttrell is a seasoned health and life science commercial executive with experience gained in large pharmaceutical companies across HIV, Rare Diseases, Oncology and Haematology. After starting his career in the pharmaceutical sector in 2002 with Eli Lilly, Matthew has held senior roles in Novo Nordisk, Gilead, GlaxoSmithKline, Shire and, most recently, Takeda. Prior to joining Oncimmune as Chief Commercial Officer, Matthew was Head of Haematology, Growth and Emerging Markets at Shire (now Takeda). Matthew’s extensive experience leading direct and indirect sales and implementing commercial strategy will enhance our commercial sales capabilities as we seek to accelerate sales of our Early CDT products. Matthew holds a bachelor’s degree in Biomedical Science, a master’s degree in Marketing Management as well as a master’s degree in Business Administration. Matthew also joins the Senior Leadership Team at Oncimmune as from 1 October 2019.

Cléa Rosenfeld joined the Oncimmune team as Head of Investor Relations in July 2019. Cléa is a senior investor relations and corporate communications professional with over 15 years of experience working in FTSE 100 and 250 companies with global businesses and international shareholder bases. Cléa was Head of Investor Relations at Shire Plc for 11 years, where she helped bring the company from a FTSE 250 Company to a top 50 FTSE company. Her significant experience within the investor relations community and her ability to develop and execute corporate strategy makes her a valuable addition to our team.

Dr Adam M Hill, Chief Executive Officer of Oncimmune Holdings commented:

“The appointments of Tariq, Matthew and Cléa add yet more expertise and depth to our leadership teams as we establish Oncimmune as a key player in supporting critical clinical decisions across the cancer care pathway. I’m delighted to welcome them and am pleased that Oncimmune’s potential attracts such high quality, experienced and seasoned professionals.

“The delivery of Oncimmune’s three-year forward strategy continues to progress at speed with the achievement of important milestones this year. The results of the landmark Scottish ECLS trial using our EarlyCDT® Lung test was presented at the World Conference for Lung Cancer on 9th September 2019. The trial further validated the use of Oncimmune’s platform technology as a screening modality, identifying cancer four years or more before standard clinical diagnosis. Our strategy is one of Partnership by Design and transactions with Biodesix in the US and R-Pharm in Russia further demonstrate the commercial potential of Oncimmune’s technology platform.”